[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Li et al., 2018 - Google Patents

The impact of liposomal linolenic acid on gastrointestinal microbiota in mice

Li et al., 2018

View PDF
Document ID
5501937192909492368
Author
Li X
Shi S
Rong L
Feng M
Zhong L
Publication year
Publication venue
International Journal of Nanomedicine

External Links

Snippet

Background The prevalence of Helicobacter pylori has long been a global health issue. Triple therapy, being the first-line treatment, has caused dysbiosis of the gastrointestinal tract that led to various complications. A novel nanomedicine–liposomal linolenic acid (LipoLLA) …
Continue reading at www.tandfonline.com (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Micro-organisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Hybridisation probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients

Similar Documents

Publication Publication Date Title
Jakubczyk et al. The effectiveness of probiotics in the treatment of inflammatory bowel disease (IBD)—a critical review
Engstrand et al. Microbiome and gastric cancer
Gan et al. Curcumin and resveratrol regulate intestinal bacteria and alleviate intestinal inflammation in weaned piglets
Tong et al. Lactobacillus rhamnosus GG derived extracellular vesicles modulate gut microbiota and attenuate inflammatory in DSS-induced colitis mice
Martín et al. Rectal and vaginal eradication of Streptococcus agalactiae (GBS) in pregnant women by using Lactobacillus salivarius CECT 9145, a target-specific probiotic strain
Sassone-Corsi et al. Microcins mediate competition among Enterobacteriaceae in the inflamed gut
Sonnenborn Escherichia coli strain Nissle 1917—from bench to bedside and back: history of a special Escherichia coli strain with probiotic properties
Gajdács et al. Microbiological and clinical aspects of cervicofacial actinomyces infections: an overview
Petrof et al. Stool substitute transplant therapy for the eradication of Clostridium difficile infection:‘RePOOPulating’the gut
Arthur et al. The complex interplay between inflammation, the microbiota and colorectal cancer
Li et al. The impact of liposomal linolenic acid on gastrointestinal microbiota in mice
Weingarden et al. Microbiota transplantation restores normal fecal bile acid composition in recurrent Clostridium difficile infection
Carvalho et al. Gut microbiome modulation during treatment of mucositis with the dairy bacterium Lactococcus lactis and recombinant strain secreting human antimicrobial PAP
Wu et al. Microbiota in the stomach: new insights
Krzyżek et al. Myricetin as an antivirulence compound interfering with a morphological transformation into coccoid forms and potentiating activity of antibiotics against Helicobacter pylori
Celiberto et al. Isolation and characterization of potentially probiotic bacterial strains from mice: Proof of concept for personalized probiotics
Jang et al. Characterization and functional test of canine probiotics
Garrido et al. Modulation of the fecal microbiota by the intake of a Lactobacillus johnsonii La1-containing product in human volunteers
Alkushi et al. Multi-strain-probiotic-loaded nanoparticles reduced Colon inflammation and orchestrated the expressions of tight junction, NLRP3 Inflammasome and Caspase-1 genes in DSS-induced colitis model
de Jesus et al. Safety evaluation of Lactobacillus delbrueckii subsp. lactis CIDCA 133: a health-promoting bacteria
Elmowalid et al. Nigella sativa extract potentially inhibited methicillin resistant Staphylococcus aureus induced infection in rabbits: potential immunomodulatory and growth promoting properties
Takáčová et al. Any future for faecal microbiota transplantation as a novel strategy for gut microbiota modulation in human and veterinary medicine?
Bunte et al. Intestinal microbiota of fattening pigs offered non-fermented and fermented liquid feed with and without the supplementation of non-fermented coarse cereals
Kommineni et al. Harnessing bacteriocin biology as targeted therapy in the GI tract
Kobatake et al. Antibacterial effects of disulfiram in Helicobacter pylori